Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Regadenoson | 3-isobutyl-1-methyl-7H-xanthine may decrease effectiveness of Regadenoson as a diagnostic agent. |
| Adalimumab | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Adalimumab. |
| Adenosine | The therapeutic efficacy of Adenosine can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine. |
| Allopurinol | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Allopurinol. |
| Carbamazepine | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Carbamazepine. |
| Cimetidine | The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Cimetidine. |
| Disulfiram | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Disulfiram. |
| Febuxostat | The serum concentration of the active metabolites of 3-isobutyl-1-methyl-7H-xanthine can be increased when 3-isobutyl-1-methyl-7H-xanthine is used in combination with Febuxostat. |
| Fluvoxamine | The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Fluvoxamine. |
| Formoterol | The risk or severity of hypokalemia can be increased when 3-isobutyl-1-methyl-7H-xanthine is combined with Formoterol. |
| Indacaterol | The risk or severity of adverse effects can be increased when 3-isobutyl-1-methyl-7H-xanthine is combined with Indacaterol. |
| Isoniazid | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Isoniazid. |
| Lithium citrate | The serum concentration of Lithium citrate can be decreased when it is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be decreased when it is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be decreased when it is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Mexiletine | The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Mexiletine. |
| Olodaterol | 3-isobutyl-1-methyl-7H-xanthine may increase the hyperkalemic activities of Olodaterol. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine. |
| Pentoxifylline | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Pentoxifylline. |
| Phenytoin | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Phenytoin. |
| Fosphenytoin | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Fosphenytoin. |
| Propafenone | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Propafenone. |
| Quinine | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Quinine. |
| Quinidine | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Quinidine. |
| Riociguat | 3-isobutyl-1-methyl-7H-xanthine may increase the hypotensive activities of Riociguat. |
| Thiabendazole | The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Thiabendazole. |
| Ticlopidine | The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Ticlopidine. |
| Zafirlukast | The serum concentration of Zafirlukast can be decreased when it is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Probenecid | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Probenecid. |
| Isoprenaline | The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Isoprenaline. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Hydroxyamphetamine | The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Metoprolol | The risk or severity of adverse effects can be increased when Metoprolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Propranolol | The risk or severity of adverse effects can be increased when Propranolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Bisoprolol | The risk or severity of adverse effects can be increased when Bisoprolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Alprenolol | The risk or severity of adverse effects can be increased when Alprenolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Pindolol | The risk or severity of adverse effects can be increased when Pindolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Carvedilol | The risk or severity of adverse effects can be increased when Carvedilol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Bevantolol | The risk or severity of adverse effects can be increased when Bevantolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |